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Background: Despite stroke’s high prevalence in the elderly, intravenous throm-
bolysis is licensed in Europe only for patients younger than 80 years old. We aimed
to compare the functional outcomes and complication rates in patients older versus
younger than 80 years old treated with intravenous thrombolysis. Methods: A ret-
rospective observational study of patients who received intravenous thrombolysis
in a stroke unit between January 1, 2009, and June 30, 2012, was conducted. Vari-
ables were compared between 2 subgroups (≤80 and >80 years). Results: Overall,
512 patients underwent intravenous thrombolysis, of which 13.1% were over 80
years. The mean age was 65.4 years in the younger subgroup and 82.9 years in
the older subgroup. Prior independence rates did not differ between the sub-
groups. Prevalence of atrial fibrillation and cardioembolic stroke was higher in
the older subgroup (P = .004 and .026). Only 3% of the elderly with atrial fibril-
lation were taking oral anticoagulants. Symptoms-to-needle time was lower in the
older subgroup (P = .048). Stroke severity was higher in patients over 80 years
(P = .026). There was significant improvement in the National Institutes of Health
Stroke Scale score 7 days after intravenous thrombolysis (P < .001) in both sub-
groups. The proportion of patients with 3 months’ favorable outcome and
independence, hemorrhagic transformation, and mortality rates were similar in
both subgroups. Conclusions: Elderly patients’ benefits and outcomes from intra-
venous thrombolysis treatment were identical to the younger subgroup without
excess hemorrhagic transformation or mortality. These results favor the use of
intravenous thrombolysis in patients over 80 years. Key Words: Stroke—elderly—
thrombolysis—over 80 years.
© 2016 National Stroke Association. Published by Elsevier Inc. All rights reserved.
Introduction
Stroke is a major cause of mortality and morbidity con-
stituting the second most frequent cause of death and
the third main cause of disability-adjusted life-years
worldwide.1
Age is the most important nonmodifiable risk factor
for stroke. In fact stroke’s incidence increases with age
in both genders, with an incidence of 38% in adults over
75 years old.2-4
However, despite stroke’s high prevalence in the elderly,
intravenous alteplase (intravenous recombinant tissue plas-
minogen activator [IV-rtPA]), the only approved treatment
for pharmacological revascularization in acute ischemic
stroke, is licensed only in Europe for use in patients
younger than 80 years old.5 This seems to be related with
frequent under-representation or exclusion of patients over
the age of 80 years from clinical trials leading to
uncertainty about the risk–benefit profile in these
patients.6
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Data regarding IV-rtPA treatment in this age group are
conflicting and result mainly from observational studies.
Most studies seem to show worse outcome and in-
creased mortality in patients aged over 80 years old with
acute ischemic stroke treated with IV-rtPA when com-
pared with younger counterparts.7-17 Nevertheless, patients
from this age group still seem to benefit from this treat-
ment and do not seem to have an increased risk of
symptomatic intracranial hemorrhage after IV-rtPA, as dem-
onstrated in several observational studies7-9,11-14,16,18-25 and
also in a randomized controlled trial.26 Thus, there is in-
creasing evidence supporting the finding that old age,
by itself, should not be a reason to exclude patients from
treatment with IV-rtPA.
Aims
In the present study, we aimed to compare the func-
tional outcomes and complication rates in patients older
versus lower than 80 years old who were treated with
IV-rtPA in our stroke unit. This study, which may be sub-
jected to the bias inherent to the retrospective analysis,
provides the benefit of the analysis on a real popula-
tion, in a real setting, facing the need for clinical decisions
in daily clinical practice.
Methods
We conducted a retrospective analysis of our prospec-
tive registry of patients who underwent IV-rtPA in our
stroke unit between January 1, 2009, and June 30, 2012.
The patients were dichotomized in 2 subgroups: pa-
tients aged 80 years or younger and patients over 80 years
old. Variables were compared between these subgroups.
Data were obtained from patient files and corporate
database and were collected in Microsoft Office Excel 2010
(Microsoft Corporation, Redmond, WA).
Informed consent for IV-rtPA was obtained from pa-
tients aged over 80 years old or their relatives.
The information collected included demographic data
(sex and age), stroke risk factors, time course data (date/
hour at the beginning of symptoms, arrival at the hospital,
arrival at the computed tomography scan room, and be-
ginning of IV-rtPA), vascular territory involved, subtype
of ischemic stroke according to the Trial of Org 10172 in
Acute Stroke Treatment (TOAST) classification, intracra-
nial hemorrhage, and mortality. Severity was assessed by
the National Institutes of Health Stroke Scale (NIHSS) (base-
line, 2 and 24 hours, and 7 days after IV-rtPA). Functional
outcomes at 90 days were measured according to modi-
fied Rankin Scale (mRS) and were assessed in a structured
follow-up medical appointment 90 days after the stroke.
The primary outcomes that were defined for the present
study were mortality rate; hemorrhagic transformation
rate per Safe Implementation of Thrombolysis in Stroke-
Monitoring Study (SITS-MOST), per European Cooperative
Acute Stroke Study 2 (ECASS-2), and per National In-
stitute of Neurological Disorders and Stroke (NINDS); and
favorable outcome after 90 days, defined as an mRS score
of 0-1 in patients aged 80 years old or younger and in
patients over 80 years old. Secondary outcomes were stroke
severity (NIHSS score) 2 and 24 hours and 7 days after
IV-rtPA and rate of independent outcome (mRS score 0-2)
and of severe disability/death (mRS score 5-6) 90 days
after stroke in both age groups.
Statistical analysis was performed in SPSS Statistics 17.0
(SPSS Inc., Chicago, IL). Continuous variables are pre-
sented as means and standard deviations, and ordinal
variables are presented as medians and interquartile ranges.
Variables were compared between 2 two age subgroups
using paired-samples t-test, independent-samples t-test,
chi-square test, and Mann–Whitney U-test as indicated.
A P value less than .05 was considered representative of
statistical significance.
Results
Study Population
A total of 512 patients underwent IV-rtPA in our unit
between January 1, 2009, and June 30, 2012. All patients
were included in the present study. Among these pa-
tients, 67 (13.1%) were aged over 80 years.
Baseline Characteristics
The baseline characteristics of the patients in the present
study are illustrated in Table 1.
The patients’ age ranged between 22 and 92 years old.
The mean age was 65.4 ± 12.3 years in the younger group
and 82.9 ± 2.4 years in the older group (P < .001). Major-
ity of the patients (56.8%) were male in the general
population. In older patients, even though most pa-
tients were males, the percentage of female patients (46.3%)
was slightly higher than that in younger patients (42.7%,
P = .582).
The functional independence before stroke, defined by
an mRS score of 1 or lower, did not differ significantly
between age groups (95.1% in younger patients, 92.5%
in older patients; P = .390).
The risk factors for stroke differed between older and
younger patients. Hypertension was the most prevalent
risk factor in both groups and was more prevalent in older
patients, but the difference was not statistically signifi-
cant (P = .066). Hyperlipidemia was the second more
common risk factor in both groups. Atrial fibrillation was
significantly more prevalent in patients over 80 years than
in younger patients (P = .004). Smoking was signifi-
cantly more likely (27.2%) in younger patients (P = .007).
Patients over 80 years were previously medicated with
acetylsalicylic acid significantly more often (37.3%) than
younger patients (20.7%) (P = .002). In both age groups,
most patients with atrial fibrillation were not medicated
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Table 1. Baseline characteristics
Characteristics Total 80 years or younger Over 80 years P OR (95% CI)
Missing data,
n (%)
Number (%) 512 445 (86.5) 67 (13.1)
Age (years), mean ± SD (min–max) 67.7 ± 13.0 (22-92) 65.4 ± 12.3 (22-80) 82.9 ± 2.4 (81-92) <.001 0 (0)
Gender, female, n (%) 221 (43.2) 190 (42.7) 31 (46.3) .582 .865 (.517-1.449) 0 (0)
Independence (mRS score 0-1) before stroke number (%) 485 (94.7) 423 (95.1) 62 (92.5) .390 1.551 (.566-4.244) 0 (0)
Risk factors Hypertension, n (%) 364 (71.1) 310 (69.7) 54 (80.6) .066 1.809 (.955-3.425 1 (.2)
Diabetes mellitus, n (%) 129 (25.2) 117 (26.3) 12 (17.9) .141 .612 (.316-1.182) 0 (0)
Hyperlipidemia, n (%) 261 (51.0) 230 (51.7) 31 (46.3) .418 .805 (.481-1.347) 3 (.6)
Smoking, current, n (%) 81 (15.8) 78 (17.5) 3 (4.5) .022 .221 (.068-.720) 1 (.2)
Smoking, previous, n (%) 48 (9.4) 43 (9.7) 5(7.5) .565 .754 (.288-1.977) 1 (.2)
Smoking, total n (%) 129 (25.2) 121 (27.2) 8 (11.9) .007 .363 (.169-.782) 1 (.2)
Previous stroke in last 3
months, n (%)
15 (2.9) 11 (2.5) 4 (6.0) .113 2.505 (.774-8.108) 0 (0)
Previous stroke more than
3 months before, n (%)
51 (10) 42 (9.4) 9 (13.4) .309 1.489 (.689-3.218) 0 (0)
Transient ischemic
accident, n (%)
10 (2) 10 (2.2) 0 (0) .215 .867 (.837-.897) 0 (0)
Atrial fibrillation, n (%) 143 (27.9) 113 (25.4) 30 (44.8) .001 2.382 (1.407-4.034) 1 (.2)
Congestive heart failure,
n (%)
107 (20.9) 87 (19.6) 20 (29.9) .053 1.751 (.987-3.107) 2 (.4)
Medication Acetylsalicylic acid
before stroke, n (%)
117 (22.9) 92 (20.7) 25 (37.3) .002 2.284 (1.323-3.941) 0 (0)
Oral anticoagulants, n (%) 15 (2.9) 13 (2.9) 2 (3.0) .977 1.022 (.226-4.635) 0 (0)
Antihypertensive
medication, n (%)
275 (53.7) 227 (51) 48 (71.6) .002 2.426 (1.382-4.259) 0 (0)
Time (min) Onset-to-door, mean ± SD 101.83 ± 51.69 104.06 ± 52.26 87.03 ± 45.37 .012 1 (.2)
Onset-to-treatment,
mean ± SD
153.16 ± 79.28 155.84 ± 82.65 135.18 ± 47.84 .048 3 (.6)
Door-to-treatment,
mean ± SD
51.32 ± 67.50 51.70 ± 71.80 48.76 ± 23.28 .741 3 (.6)
Abbreviations: CI, confidence interval; mRS, modified Rankin Scale; OR, odds ratio; SD, standard deviation. Numerals in bold represent statistically significant associations (P < 0.05)
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with oral anticoagulants (88.5% and 93.3% in the younger
and older groups, respectively) and many hypertensive
patients were not using antihypertensive medication (26.8%
and 11.1% in the younger and older groups, respectively).
Stroke onset-to-door and onset-to-treatment times were
significantly shorter in patients over 80 years (P = .012
and .048, respectively). There were no significant differ-
ences in door-to-treatment times between groups.
Stroke-Related Characteristics
Data regarding baseline stroke severity, vascular ter-
ritory involved, and stroke subtype according to TOAST
classification are shown in Table 2.
Baseline stroke severity was significantly higher (P < .001)
in patients over 80 years (median NIHSS score 15 ± 12)
than in younger patients (median NIHSS score 10 ± 10).
Most strokes were located in anterior circulation in both
age subgroups. Anterior circulation strokes were more
frequent among older (64.2%) than younger patients
(52.1%), but there were no statistically significant differ-
ences regarding location of stroke (P = .216).
Globally, cardioembolic stroke was the most preva-
lent subtype, according to TOAST classification, and was
more likely to occur in older patients, even though, glob-
ally, no statistically significant differences were found in
stroke subtypes (P = .301).
Clinical Outcome and Hemorrhagic Transformation
Table 3 and Figure 1 summarize data on clinical out-
comes and hemorrhagic transformation.
Stroke severity was still significantly higher in older
patients either 2 hours (P = .023) or 7 days (P = .025) after
IV-rtPA (Table 3).
However, there were no significant differences in 3
months’ outcome between the 2 age groups, with a similar
proportion of patients in both groups reaching favor-
able outcome (Table 3).
There were also no significant differences in mortali-
ty (P = .864) or hemorrhagic transformation rates (P = .559
per SITS-MOST, P = .670 per ECASS-2, and P = .529 per
NINDS) between older and younger patients.
Discussion
Stroke in patients over 80 years has unique character-
istics if compared with younger patients.
In our study, older patients’ most prevalent risk factor
was hypertension, similar to younger patients. Unlike other
studies such as that of García-Caldentey et al,14 even though
hypertension was more frequent in older than in younger
patients, this difference did not achieve statistical signif-
icance. The prevalence of diabetes mellitus tended to be
higher in younger than in older patients (not statistical-
ly significant), possibly partially due to an increase of the
prevalence of diabetes in younger patients that may be
related with changes in food habits and exercise. Older
patients were, however, significantly more likely to have
atrial fibrillation than younger patients, as described in
previous studies.12,14,27 Moreover, cardioembolism as the
main etiology was also observed in a higher proportion
of older patients. Nevertheless, despite the finding that
44.8% of patients over 80 years had atrial fibrillation, only
3.0% of the patients were previously medicated with oral
anticoagulants. This finding may be related with
underdiagnosis of atrial fibrillation in some cases and pos-
sibly also with undermedication of previously diagnosed
patients. Thus, one of the issues that the present study
points out is the possible room for optimizing the primary
prevention of stroke in older patients by ensuring active
search for this arrhythmia and initiation of anticoagula-
tion, providing there are no contraindications.
Also with reference to the vascular risk factors
and previous medication, older patients were signifi-
cant less likely to be current smokers, as described
in previous studies,12,14,27 and were more likely to be
Table 2. Stroke-related characteristics
Characteristics Total
80 years or
younger Over 80 years
Missing data,
n (%) P
NIHSS score on admission, median ± IQR 11 ± 10 10 ± 10 15 ± 12 0 <.001
Location, n (%) Anterior 275 (53.7) 232 (52.1) 43 (64.2) 196 (38.3) .216
Posterior 26 (5.1) 23 (5.2) 3 (4.5)
Anteroposterior 5 (1) 5 (1.1) 0
TOAST classification, n (%) Large-artery atherosclerosis 50 (9.8) 43 (9.7) 7 (10.4) 133 (35) .301
Small-vessel occlusion 78 (15.2) 68 (15.3) 10 (14.9)
Cardioembolism 134 (26.2) 109 (24.5) 25 (37.3)
Undetermined etiology 95 (18.6) 84 (18.9) 11 (16.4)
Other determined etiology 22 (4.3) 22 (4.9) 0
Abbreviations: IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; TOAST, Trial of Org 10172 in Acute Stroke
Treatment. Numerals in bold represent statistically significant associations (P < 0.05)
THROMBOLYSIS IN PATIENTS OVER 80 YEARS IS EFFECTIVE AND SAFE 1535
medicated with acetylsalicylic acid and antihyperten-
sive medication. This finding is presumably associated
with a greater number of comorbidities as age in-
creases. Also, many patients with hypertension were not
medicated with antihypertensive therapy.
We also point out that there was no significant differ-
ence in previous functional status (mRS score) between
older and younger patients, emphasizing that although
many patients over 80 years were treated with IV-rtPA,
their previous functional status was good. This is in con-
trast with some of the previous studies.12,16 In a recent
study by Ford et al,16 previous independence before stroke
was significantly less frequent in older than in younger
patients. In Ford et al’s study, IV-rtPA in older patients
was associated with increased mortality and poorer
outcome.
There was a significant difference in onset-to-door and
onset-to-treatment times between age groups, which were
significantly shorter in older patients. That was possi-
bly explained by a more careful selection of patients over
80 years old who were adequate candidates to IV-rtPA,
given that shorter time to treatment increases benefit and
decreases risk,28 and taking into account the more dubious
safety/benefit profile of these patients. Another possi-
ble contributing explanation may be the geographical
context of the hospital with an elderly population living
near the hospital, consequently having a quicker access.
The safety/benefit profile of IV-rtPA in older patients
has been the subject of controversy for the past years.29
The results of our study show that, as previously
reported,9,10,16 older patients tend to experience strokes with
higher severity than younger patients (median NIHSS score
of 15 versus 10). Despite these results, older patients
still benefited from IV-rtPA. In fact, there were no
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Figure 1. Three-month mRS outcomes in patients 80 years or younger
and in patients over 80 years old. Abbreviation: mRS, modified Rankin
Scale.
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significant differences in favorable outcome or indepen-
dent outcome at day 90 between younger and older
patients. Most previous studies had shown lower rates
of favorable and independent outcomes at day 90 in patient
aged over 80 years old.7,12,15,16 However, a recent ran-
domized controlled trial including 1617 patients over 80
years suggested that benefit does not seem to be dimin-
ished in the elderly.26 Also, in a study by Zeevi et al,19
older patients treated with IV-rtPA presented with a 12-
month modified Barthel Index score comparable to that
of younger patients. Moreover, several studies revealed
a similar rate of early neurological improvement in younger
and older patients,7,9 and higher rates of early neurolog-
ical improvement21 and improved functional outcome
among elderly patients who underwent thrombolysis versus
elderly patients who did not undergo thrombolysis.8,25
In the present study, hemorrhagic transformation or
mortality rates at day 90 were similar in older and
younger patients. Many other studies had previously re-
ported similar rates of symptomatic and asymptomatic
intracranial hemorrhages between younger and older
patients.7,9,11,14-16,19,20,23,24 In contrast to our study,
most previous studies revealed an increased 30-day
mortality.7,9-11,13-16,24
So, according to our results, older patients seem to also
be likely to benefit in the short and long term from IV-
rtPA and do not seem to be in increased risk of mortality
or hemorrhagic transformation.
Age by itself should not be a reason for exclusion of
patients over 80 years from treatment with IV-rtPA. The
positive results obtained must, however, be interpreted
in light of a careful selection of patients as illustrated by
the patients’ favorable previous functional status or onset-
to-treatment time. The necessity of adequate monitoring
and level of care, evidence-based protocols, personnel train-
ing, and experience must also be noted to improve
outcomes.
Our study has 2 main limitations. First, being a ret-
rospective analysis of a prospective registry, we cannot
exclude selection bias, including referral bias, of older pa-
tients, mostly because healthy elderly are possibly more
likely to be referred and transferred for IV-rtPA. Second,
the small sample size prevents the present study to detect
small differences in infrequent outcomes.
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